MedTrace Logo

Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

NCT05958134 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-05-23

No results posted yet for this study

Summary

National, multicenter, non-randomized, retrospective observational study (Real World Evidence-RWE) to analyze the epidemiological profile of diffuse large B cell lymphoma, clinical management, treatment in molecular subgroups, progression profile and patient survival outcomes enrolled and treated within the last 6 years (2017 to 2022), in national cancer reference centers.

Conditions

Sponsors & Collaborators

  • Hospital Israelita Albert Einstein

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Guilherme Fleury Perini · Hospital Israelita Albert Einstein

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-15
Primary Completion
2024-06-06
Completion
2024-06-06

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05958134 on ClinicalTrials.gov